Compare Eli Lilly And Co (LLY) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Southwest Airlines Co — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Southwest Airlines Co trades at $41.66 (market cap $20.23B). The key difference: Eli Lilly And Co is far larger — about 51.4× Southwest Airlines Co's market cap, and Southwest Airlines Co pays the higher dividend (1.74%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Southwest Airlines Co for 65 Days on average.
| LLY | LUV | |
|---|---|---|
Market Cap | $1.04T | $20.23B |
Volume | 3,064,878 | 14,560,422 |
Sector | Health | Industrials |
52-Week High | $1.28K | $54.80 |
52-Week Low | $799.57 | $29.67 |
Typical Hold Time | 93 Days | 65 Days |
Enterprise Value | $1.09T | $23.33B |
Dividend Yield | 0.59% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Southwest Airlines (LUV) trades at $41.66, down 0.14% with a bearish technical signal. The stock shows mixed earnings performance with a recent Q2 beat but Q1 miss. Valuation metrics appear reasonable with P/E of 25.85 and P/S of 0.72. The company is undergoing a commercial transformation with new fare structures expected to generate significant EBIT growth, though net margins remain thin at 2.78%. Cash flow trends show improvement projected for 2026 with positive net cash flow of $316M.
LUV presents a turnaround opportunity with its revenue transformation initiatives targeting over $2 billion EBIT in 2026. The 19% upside to consensus price target of $49.61 offers potential reward, but risks include high fuel costs, competitive pressure from legacy carriers, and execution challenges. Analyst sentiment is mixed with 42% buy ratings amid ongoing operational changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
